<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities and Exchange Act of 1934
(Amendment No. 1)*
Anesta Corp.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
034603100
--------------------------------------------------------------------------------
(CUSIP Number)
June 22, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 4 pages
<PAGE>
CUSIP No. 034603100
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abbott Laboratories
IRS Identification No. 36-0698440
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
--------------------------------------------------------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES 537,840
BENEFICIALLY --------------------------------------------
OWNED BY EACH 6. SHARED VOTING POWER
REPORTING PERSON WITH 0
--------------------------------------------
7. SOLE DISPOSITIVE POWER
537,840
--------------------------------------------
8. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
537,840
--------------------------------------------------------------------------------
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.02% (see Item 5 below)
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
--------------------------------------------------------------------------------
Page 2 of 4 pages
<PAGE>
The following information amends and supplements the original Schedule 13G filed
by Abbott Laboratories on February 10, 1995.
Item 1(a) Name of Issuer:
Anesta Corp.
Item 1(b) Address of Issuer's Principal Executive Offices:
4745 Wiley Post Way
Salt Lake City, UT 84116
Item 2(a) Name of Persons Filing:
Abbott Laboratories
Item 2(b) Address of Principal Business Office:
100 Abbott Park Road
Abbott Park, Illinois 60064-6049
Item 2(c) Citizenship:
Illinois.
Item 2(d) Title of Class of Securities:
Common Stock, par value $.001 per share
Item 2(e) CUSIP Number:
034603100
Item 4. Ownership
Reference is hereby made to Items 5-9 and 11 of page 2 of this
Schedule 13G, which Items are incorporated by reference herein.
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the beneficial owner of
more than 5 percent of the class of securities, check the following [X].
Page 3 of 4 pages
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: June 27, 2000 Abbott Laboratories
By: /s/ Gary P. Coughlan
------------------------------------------------
Gary P. Coughlan, Senior Vice President, Finance
and Chief Financial Officer
Page 4 of 4 pages